Clinical trial
Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination
NCT02225327 is registered in ClinicalTrials.gov with Korea University Guro Hospital as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Immunogenicity and Safety of MF59-adjuvanted Trivalent Influenza Vaccine (Fluad) and 23-valent Pneumococcal Polysaccharide Vaccine (PPV23) in the Elderly: Single Versus Concomitant Vaccination
- Lead sponsor
- Korea University Guro Hospital
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- October 31, 2013
- Completion date
- January 31, 2014
- Enrollment
- 224 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.